SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Matritech (NASDAQ - NMPS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: M.A. Caccavo who wrote (628)5/20/1998 11:53:00 AM
From: Damon Pham   of 849
 
FDA Ruling Not Big Impediment, Analyst Says

(Copyright (c) 1998, Dow Jones & Company, Inc.)

Gary B. Davis, an analyst at Jesup & Lamont Securities, said the FDA
510(k) ruling doesn't necessarily represent a major problem for
Matritech because the company also is pursuing pre-market approval for
NuMA.
The decision is "no reflection on the safety or efficacy of the
products," he said.
The analyst estimates that the 510(k) rejection will cause a delay of
six to nine months in the market introduction of NuMA.
Further, Davis said the NuMA test is only "one of multiple products,"
offered by Matritech, and that a delay in its release will not affect
the company's performance severely.
Company officials were not immediately available for comment.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News